Quvara Medical

Quvara Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Quvara Medical is a specialized contract manufacturer for regulated, high-volume medical devices, operating from a large-scale facility in Swindon, UK. The company differentiates itself through a platform-first manufacturing approach, deep integration of validation and regulatory compliance (ISO 13485, FDA 21 CFR Part 820), and a partnership model aimed at long-term supply resilience for pharma and biotech clients. With 350 employees and 24/7 operations, it focuses on reducing risk and accelerating launch timelines for drug-device combination products, serving as a critical dual-sourcing partner in the global supply chain.

Medical DevicesDigital Health

Technology Platform

Platform-first manufacturing for autoinjectors and pen injectors, integrating high-volume injection moulding, automated assembly, in-line inspection, and digital quality systems within ISO cleanrooms. Focus on scalable platforms that accommodate device variants to reduce validation burden.

Opportunities

The company is positioned to capitalize on the growing biologics market, which drives demand for sophisticated, patient-friendly autoinjectors and pen injectors.
Trends towards outsourcing, supply chain dual-sourcing, and the need for regulatory expertise in combination products present significant growth opportunities for a specialized CMO like Quvara.

Risk Factors

Key risks include customer concentration, as reliance on a few large clients (including a major med-tech company) could impact stability.
Regulatory non-compliance risks are ever-present in medical device manufacturing, and intense competition in the CMO space pressures margins and client retention.

Competitive Landscape

Quvara competes in the contract manufacturing segment for drug-delivery devices against large, diversified CMOs and other specialized device manufacturers. Its differentiation lies in a dedicated focus on high-volume, regulated platform manufacturing, integrated validation, and a partnership model aimed at long-term supply resilience rather than transactional projects.